Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years, with the exception of those with a negligible risk of metastases or death, such as carcinoma in situ of the breast or cervix
Prior invasive malignancy (except non-melanomatous skin cancer or other in-situ malignancies, or stage Ta bladder cancer) unless disease free for a minimum of 2 years
Co-existing or prior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a minimum of 3 years; previous RT dose, date, fraction size, must be reported
Prior invasive malignancy (except non-melanomatous skin cancer, curatively resected thyroid papillary carcinoma, and invasive and non-invasive cancers related to the breast cancer) unless disease free for a minimum of 3 years
Subject has another active malignancy other than non-melanomatous skin cancer (unless it is metastatic) or superficial bladder cancer
Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ? 3 years.
Previous malignancy (except for non-melanomatous skin cancer) < 5 years
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 1 year
Confirmed diagnosis of another malignancy within the past 6 months\r\n* Non-melanomatous skin lesions are acceptable
Prior history of invasive malignancy, except non-melanoma skin cancer, unless disease free for >= 3 years (yrs)
Prior invasive non-breast malignancy (except non-melanomatous skin cancer, carcinoma in situ of the cervix) unless disease free for a minimum of 3 yrs prior to study entry
Prior history of invasive non-breast malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1 year prior to registration
Presence of a second malignancy, excluding non-melanomatous skin cancer unless in remission for 3 years
Patients with an active second malignancy or prior invasive malignancy unless disease free for a minimum of 3 years; non-melanoma skin cancer and previous early prostate cancer that had a non-rising PSA can be enrolled
Patients diagnosed with invasive malignancy are not eligible (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (e.g., oral cavity)
Prior invasive malignancies (except non-melanomatous skin cancers and carcinoma in situ of the cervix or bladder) unless disease free for >= 5 years
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
Evidence of metastatic disease, unless disease-free for >= 3 years prior to registration, (non-melanomatous skin cancer and in-situ cancers are okay)
Prior invasive (except non-melanoma skin cancer) malignancy unless disease-free for a minimum of 2 years
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
Prior or concurrent invasive malignancy (except non-melanomatous skin cancer or lymphomatous/hematogenous malignancy) unless continually disease free for a minimum of 5 years
Patients with history of prior invasive malignancy (except non-melanomatous skin cancer and glioblastoma diagnosis) must have been disease free for a minimum of 1 year
Prior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a minimum of 3 years
Prior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a minimum of 3 years
Other malignancy, except non-melanomatous skin cancer, < 5 years prior to participation in this study; the disease-free interval from any prior carcinoma must be continuous
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years, with the exception of those with a negligible risk of metastases or death, such as carcinoma in situ of the breast or cervix
Prior invasive malignancy that is not low-grade glioma (except non-melanomatous skin cancer or carcinoma in situ of the cervix) unless the patient has been disease free and off therapy for that disease for a minimum of 3 years
Prior invasive malignancy within the past 3 years (except for non-melanomatous skin cancer, and early stage treated prostate cancer)
No prior invasive malignancy in the past 3-years, except non-melanomatous skin cancer unless disease free for a minimum of 2 years; carcinoma in-situ of the bladder or head and neck region is permissible
Prior invasive malignancy (except for non-melanoma skin cancer) unless disease free for >= 3 years
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
Patient is < 2 years free from a second primary malignancy unless the other malignancy is non-melanomatous skin cancer or an in-situ tumor treated with curative intent
Prior invasive malignancy (unless disease free for a minimum of 1095 days [3 years]); non-melanomatous skin cancer and previous early prostate cancer that had a non-rising prostate-specific antigen (PSA) are eligible
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 3 years
Previous malignancy within 3 years other than non-melanomatous skin cancer and non-muscle invasive bladder cancer
Prior invasive malignancy unless disease-free for a minimum of 5 years
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
Prior invasive non-breast malignancy unless disease free for a minimum of 1 year prior to registration
Prior invasive malignancy (except non-melanomatous skin cancer) or hematological (e.g., leukemia, lymphoma, myeloma) malignancy unless disease free for a minimum of 5 years (prior diagnoses of carcinoma in situ are permitted)
Participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that she has been disease free for > 3 years
Prior invasive malignancy (except non-melanoma skin cancer) unless disease- free or not requiring systemic therapy for a minimum of 3 years
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 3 years or if cure rate from treatment at 5 years to be 90% or greater
Prior invasive malignancies (except non-melanomatous skin cancers and carcinoma in situ of the cervix or bladder) unless disease free for >= 5 years
History of another malignancy within the previous 5 years other than non-melanomatous skin cancer
Prior invasive malignancy that is not low-grade glioma, glioblastoma or gliosarcoma (except non-melanomatous skin cancer or carcinoma in situ of the cervix) unless the patient has been disease free and off therapy for that disease for a minimum of 3 years
Prior or concurrent second invasive malignancy other than non-melanoma skin cancer, unless disease free for a minimum of five years
No invasive malignancy within the past 5 years except resected non-melanomatous skin cancer, papillary thyroid cancer, or precancerous cervical dysplasia.
Prior invasive solid tumor or hematological malignancy (except non-melanomatous skin cancer and incidentally discovered prostate cancer at time of cystoprostatectomy) unless disease free for a minimum of 3 years
Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease free for a minimum of 5 years
Patient is free of any prior invasive malignancy (except non-melanomatous skin cancer) for a minimum of the past 3 years
Concurrent malignancy except non-melanomatous skin cancer or prior cancer if disease-free for one year or more
Prior invasive malignancy except non-melanomatous skin cancers unless patient has been disease free for at least 3 years
Prior invasive malignancy that is not low-grade glioma, high-grade glioma, glioblastoma, or gliosarcoma (except non-melanomatous skin cancer or carcinoma in situ of the cervix) unless the patient has been disease free and off therapy for that disease for a minimum of 3 years.
Prior invasive malignancy that is not the ependymoma (except non-melanomatous skin cancer or carcinoma in situ of the cervix) unless the patient has been disease free and off therapy for that disease for a minimum of 3 years
Concomitant invasive malignancy requiring treatment other than non-melanomatous skin cancer
Subject has had any other prior invasive malignancy, unless disease-free for a minimum of 3 years.
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
Prior history of any other malignancy within past three years, except melanomatous skin cancer or carcinoma in situ.
Prior invasive malignancy (except non-melanomatous skin cancer or disease free for at least 3 years)
Prior invasive malignancy, except non-melanoma skin cancer, carcinoma in-situ of the bladder or head and neck region, unless disease free for a minimum of 2 years
